Treatment of oligometastatic lung cancers: new data, new drivers, new approaches.

The oligometastatic paradigm has expanded the use of stereotactic ablative radiotherapy (SABR) and local consolidative therapy (LCT) in metastatic non-small cell lung cancer (NSCLC), but accumulating evidence suggests that 'oligometastatic NSCLC' is not a single clinical entity. As systemic therapy has advanced-particularly third-generation EGFR tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors-both the intent and the incremental value of local therapy have diverged by molecular subtype, metastatic tempo and treatment setting. In EGFR-mutated disease, multiple prospective studies now support LCT as a strategy to extend durable benefit from TKIs by ablating limited sites of disease, with contemporary randomised data emerging in the osimertinib era and ongoing trials addressing optimal timing and completeness of consolidation. In driver-negative, immunotherapy-treated NSCLC, early phase and real-world series suggest that carefully selected patients can achieve durable control within multimodality pathways, but the most practice-defining randomised evidence to date has not supported routine consolidation for all non-progressing patients and highlights pneumonitis risk, reinforcing the need for stringent staging and selection. Management of EGFR-mutated small and non-symptomatic brain metastases has similarly evolved towards systemic-first sequencing with selective stereotactic radiosurgery for high-risk lesions or focal central nervous system escape, informed by emerging randomised data. Across settings, lesion count alone is an imperfect surrogate for biology; metastatic tempo, molecular drivers and treatment response patterns are increasingly relevant to deciding when SABR should be comprehensive, selective or deferred. Ongoing trials in targeted and immunotherapy eras will determine when LCT should be integrated as standard care versus an optimisation strategy for a minority. We propose a pragmatic framework centred on treatment intent-comprehensive ablation for potentially curable limited disease versus focal ablation to maintain an effective systemic agent-aimed at supporting multidisciplinary decision-making as the evidence base evolves.